InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,985.38
(
0.00%
)
US TECH 100
20,511.20
(
0.10%
)
Dow Jones
43,958.19
(
0.00%
)
Brent Oil
72.85
(
1.37%
)
Bitcoin
90,996.29
(
0.48%
)
Post# of 253594
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120719
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 110854

Tuesday, 05/17/2011 2:38:00 PM

Tuesday, May 17, 2011 2:38:00 PM

Post# of 253594
AMGN reports additional Xgeva data from phase-3 trial for prevention of bone mets in patients with CRPC:

http://www.reuters.com/article/2011/05/17/amgen-xgeva-idUSN1716488420110517

AMGN reported in Dec 2010 that Xgeva produced a statsig increase in PFS in this indication (#msg-57720261); the new data on secondary endpoints do not change the prospects for Xgeva to a material degree, IMO.

A table of the phase-3 results for Xgeva/Prolia is in #msg-57938233.

“The notion that there’s a Chinese Wall between sell-side analysts
and investment bankers may be the second-biggest piece of BS
ever promulgated in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up